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ORIGINAL ARTICLE
Background/Aims: This study was undertaken to identify the intracellular signaling pathway involved in
induction of macrophage migration inhibitory factor (MIF) in human rheumatoid arthritis (RA) synovial fibroblasts.  
Methods: Human RA synovial fibroblasts were treated with concanavalin A (ConA), various cytokines, and
inhibitors of signal transduction molecules. The production of MIF by synovial fibroblasts was measured in
culture supernatants by ELISA. The expression of MIF mRNA was determined using reverse transcriptase
polymerase chain reaction (RT-PCR) and real-time PCR. Phosphorylation of p38 mitogen-activated protein
(MAP) kinase in synovial fibroblasts was confirmed using Western blotting. The expression of MIF and p38 MAP
kinase in RA synovium was determined using dual immunohistochemistry.   
Results: The production of MIF by RA synovial fibroblasts increased in a dose-dependent manner after ConA
stimulation. MIF was also induced by interferon-γ, CD40 ligand, interleukin-15, interleukin-1β, tumor necrosis
factor-α, and transforming growth factor-β. The production of MIF by RA synovial fibroblasts was significantly
reduced after inhibition of p38 MAP kinase. The expression of MIF and p38 MAP kinase was upregulated in the
RA synovium compared with the osteoarthritis synovium.  
Conclusions: These results suggest that MIF production was induced through a p38 MAP-kinase-dependent
pathway in RA synovial fibroblasts. (Korean J Intern Med 2010;25:317-326)
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INTRODUCTION
Many cytokines play a central role in the formation of
complex networks and cross-regulation to induce, augment,
and regulate inflammatory cells in the pathogenesis of
rheumatoid arthritis (RA) [1]. Inhibitors of various cytokines
are used as effective therapeutic tools for severe RA.
However, biological therapy, such as tumor necrosis factor
(TNF)-α- or interleukin (IL)-1β-neutralizing agents have
some limitations because blocking one cytokine gives
incomplete control of pathogenesis in diseases that
involve complex cytokine networks [1,2]. Therefore,
combination therapy that blocks two cytokines or a
cytokine and another signal transduction molecule is
needed. 
Concanavalin A (ConA) is a potential multi-receptor
crosslinker for T-cell receptor and other cell-surface
receptors. It is the most extensively investigated memberof the lectin family of plant proteins and displays high
affinity for terminal -D-mannosyl and -D-glucosyl residues
[3]. ConA exhibits cell agglutinating and mitogenic
activities and induces apoptosis [4]. ConA is a tetravalent
lectin and is known to trigger augmented secretion and
proteolytic activation of matrix metalloproteinases
(MMPs) in fibroblasts; hence, it is widely used for the
study of MMP secretion [5,6].
Macrophage migration inhibitory factor (MIF) is an
important inflammatory cytokine in RA. MIF activates
macrophages to induce the release of pro-inflammatory
cytokines such as TNF-α, IL-1, and IL-6 and to promote
interferon (IFN)-γ-induced production of nitric oxide
[7,8]. MIF activates RA fibroblast-like synoviocytes (FLSs)
to produce cyclooxygenase 2 (COX-2), MMP-1, and MMP-
3, which contribute to tissue destruction [9,10]. MIF also
upregulates MMP-13 mRNA [11], suppresses p53-mediated
events in the inflamed synovium, and inhibits apoptosis
of damaged cells [12,13]. The imbalance between the
proliferation and apoptosis in the synovial cells results in
tissue expansion in the RA synovium. Our previous study
has shown that MIF controls angiogenesis in RA synovial
fibroblasts by producing vascular endothelial growth
factor (VEGF) and IL-8 and by inducing endothelial tube
formation [14]. The presence of MIF reflects clinical
disease activity in RA patients and might be useful as a
clinical disease marker [14,15].
Although activated T cells are the main source, MIF is
also expressed abundantly by FLSs and macrophages in
the RA synovium, and FLS-derived MIF upregulates the
release of TNF-αand IL-1β, suggesting that MIF acts as an
upstream member of the network of cytokines that are
operative in RA [7,14,16]. Recent data suggest that MIF
regulates RA synovial hyperplasia by acting directly and
indirectly via TNF-α and IL-1β. In addition, the effects of
MIF on FLS activation and proliferation are dependent on
extracellular signal-regulated kinase (ERK) and mitogen-
activated protein (MAP) kinase, but are independent of
nuclear factor-κB (NF-κB) [16,17]. Recombinant MIF
activates RA FLSs to produce COX-2 and IL-6 via the p38
MAP kinase pathway [18]. Although the intracellular
mechanism responsible for the effects of MIF on target
cells has been investigated, the intracellular mechanism
that underlies the activation of MIF in target cells such as
RA synovial fibroblasts is unknown. We identified the
signal transduction pathway involved in MIF induction
after the stimulation of FLSs.
METHODS
Isolation and culture of FLSs
Synoviocytes were isolated by enzymatic digestion of
synovial tissues obtained from patients with RA and
osteoarthritis (OA) who were undergoing total joint
replacement surgery. The tissues were minced into 2 to
3-mm pieces and treated for 4 hours with 4 mg/mL of
type I collagenase (Worthington Biochemical, Freehold,
NJ, USA) in Dulbecco’s Modified Eagle’s Medium (DMEM)
at 37˚Cin 5% CO2. Dissociated cells were then centrifuged
at 500 g, resuspended in DMEM supplemented with 10%
fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL
penicillin, and 100 µg/mL streptomycin, and plated in 75-
cm2 flasks. After overnight culture, the nonadherent cells
were removed, and the adherent cells were cultivated in
DMEM supplemented with 20% FBS. The cultures were
kept at 37˚C in 5% CO2, and the medium was replaced
every 3 days. When the cells approached confluence,
they were passed after 1:3 dilution with fresh medium.
Synoviocytes from passages 4 to 8 were used in each
experiment. The cells were morphologically homogeneous
and exhibited the appearance of synovial fibroblasts, with
typical bipolar configuration under inverse microscopy.
The purity of the cells (1 ×104) was tested by flow cytometry
using phycoerythrin-conjugated anti-CD14 and
fluorescein-isothiocyanate-conjugated anti-CD3 or anti-
Thy-1 (CD90) monoclonal antibodies (all from
Pharmingen). At passage 4, most cells (> 95%) expressed
the surface markers for fibroblasts (Thy-1), whereas 3.5%
of cells were CD14+, and < 1% of cells were CD3+.
Measurement of MIF concentration in culture
supernatants
MIF concentration was measured in culture supernatants
by sandwich ELISA, as described previously [19]. Ninety-
six-well plates were coated with 100 µL per well of 0.4
µg/mL goat anti-human MIF (R&D Systems, Minneapolis,
MN, USA) buffered with 50 mM sodium bicarbonate (pH
9.6). After overnight incubation at 4˚C, the plates were
blocked with 1% bovine serum albumin (BSA) in PBS for 2
hours at room temperature. The human recombinant MIF
(R&D Systems) or culture supernatant was added to the
wells and then incubated for 2 hours at room temperature.
Plates were incubated with 0.2 µg/mL of biotinylated goat
anti-human MIF (R&D Systems) at room temperature for
2 hours. Peroxidase-labeled ExtrAvidin (Sigma Chemical
Co., St. Louis, MO, USA), diluted 1:2,000, was added, and
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hours. A color reaction was induced by the addition of
tetramethylbenzidine/H2O2 substrate solution and was
stopped 30 minutes later by the addition of 1 M phosphoric
acid. An automated microplate reader was used to
measure the optical density at a wavelength of 450 nm.
Between steps, plates were washed four times with PBS
containing 0.05% Tween 20. Human recombinant MIF,
diluted in culture medium over a concentration range of
10 to 2,000 pg/mL, was used as a calibration standard.
Measurement of MIF mRNA expression using
reverse transcriptase polymerase chain reaction
(RT-PCR)
mRNA was extracted from FLSs using RNAzol B
according to the manufacturer’s instructions (Biotex
Laboratories, Houston, TX, USA). Two micrograms of
total mRNA was reverse transcribed at 42˚C using the
Superscript™ Revere Transcription System (Gibco BRL,
Grand Island, NY, USA). PCR amplification of cDNA
aliquots was performed by adding 2.5 mM dNTPs, 2.5 U
Taq DNA polymerase (Takara, Shiga, Japan), and 0.25 µM
of sense and antisense primers. The reaction was
performed in PCR buffer (1.5 mM MgCl2, 50 mM KCl, 10
mM Tris HCl, pH 8.3) in a total volume of 25 µL. The
primers used were MIF, 5’-GAACCGCTCCTACAGCAAGCT-
3’ (forward) and 5’-GCGAAGGTGGAGTTGT
TCCA-3’ (reverse), and GAPDH, 5’-CGATGCTGGGCGTGAGTAC-
3’ (forward) and 5’-GTTCAGTCCAGGGATGACC-3’
(reverse), which yielded PCR products of 381 and 300 bp,
respectively. Reactions were processed in a DNA thermal
cycler (PerkinElmer Cetus, Norwalk, CT, USA) through
cycles of 30-second denaturation at 94˚C, 1 minute
annealing at 55˚C for GAPDH and at 56˚C for MIF,
followed by 30-second elongation at 72˚C. PCR rounds
were repeated for 25 cycles for GAPDH and 35 cycles for
MIF, which were determined to fall within the exponential
phase of amplification for each molecule. The level of
mRNA expression was presented as the ratio of MIF PCR
product to GAPDH product.
Real-time PCR with SYBR Green
mRNA was extracted using RNAzol B (BioTex
Laboratories) according to the manufacturer’s
instructions. Reverse transcription of 2 µg total mRNA
was conducted at 42˚C using the Superscript Reverse
Transcription System (Takara). PCR amplification of
cDNA aliquots was performed by adding 2.5 mM dNTPs
and 2.5 U Taq DNA polymerase (Takara), and human
MIF was amplified using the sense primer 5’-
CCGGACAGGGTCTACATCAACTATTAC-3’ and the anti-
sense primer 5’-TAGGCGAAGGTGGAGTTGTTCC- 3’ in a
LightCycler™ (Roche Diagnostics, Mannheim, Germany).
The relative expression levels were calculated by
normalizing the MIF levels to the endogenously expressed
housekeeping gene β-actin. Melting curve analysis was
performed immediately after the amplifi-cation protocol
under the following conditions: 0 second (hold time) at
95˚C, 15 seconds at 65˚C, and 0 second (hold time) at
95˚C. The temperature change rate was 20˚C/sec except
in the final step, when it was 0.1˚C/sec. The crossing point
(Cp) was defined as the maximum of the second derivative
from the fluorescence curve.
Analysis of MAP kinase activation
The activation of ERK was antagonized with a specific
inhibitor of MAP kinase/ERK kinase kinase (MEKK),
PD98059 (Calbiochem, San Diego, CA, USA), and the
specific p38 MAP kinase inhibitor was SB203580
(Calbiochem). The activation of NF-κB, activator protein 1,
c-Jun N-terminal kinase (JNK), and Akt was antagonized
with pyrollidine dithiocarbamate (PDTC; Sigma),
curcumin (Sigma), JNK inhibitor (Calbiochem), and
phosphoinositide 3-kinase (PI3K) inhibitor (Calbiochem),
respectively. The phosphorylation of p38 MAP kinase
was assessed using Western blotting with monoclonal
antibodies specific for the phosphorylated (activated)
form of p38 MAP kinase. RA synovial fibroblasts were
stretched in the absence or presence of the pathway
inhibitors indicated above for 1 hour. At various times,
cells were scraped into lysis buffer, and the protein
content was measured using the BioRad DC protein assay
(BioRad Laboratories, Hercules, CA, USA). Equal amounts
of protein were resolved by SDS-PAGE, transferred to a
polyvinylidene fluoride membrane, and blotted with
antibodies to the phosphorylated and nonphosphorylated
forms of p38. A rabbit peroxidase-conjugated anti-rabbit
antibody was used as the secondary antibody, and the
binding was revealed by chemiluminescence reagents
(ECL; Amersham Pharmacia Biotech, Piscataway, NJ,
USA) according to the manufacturer’s instructions.
Immunohistochemistry of RA synovium
Immunohistochemical staining for MIF and p38 MAP
kinase was performed on sections of synovium. The
synovial samples were obtained from RA patients, fixed
Kim HR, et al. Induction of MIF in RA-FLS via p38    319in 4% paraformaldehyde solution overnight at 4˚C,
dehydrated with alcohol, washed, embedded in paraffin,
and sectioned into 7-µm-thick slices. The sections were
depleted of endogenous peroxidase activity by adding
methanolic H2O2and then blocked with normal serum for
30 minutes. After overnight incubation at 4˚C with
polyclonal anti-human MIF and anti-p38 antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), the
samples were incubated with the secondary antibody,
biotinylated anti-rabbit IgG or biotinylated anti-goat
IgG, for 20 minutes, and incubated with streptavidin-
peroxidase complex (Vector, Peterborough, UK) for 1
hour, followed by incubation with 3,3’-diaminobenzidine
(Dako, Glostrup, Denmark) for 5 minutes. The sections
were counterstained with hematoxylin. Samples were
photographed with an Olympus photomicroscope (Olympus,
Tokyo, Japan).
Dual immunohistochemistry
Dual immunohistochemical labeling (MIF and p38) was
performed using the DakoCytomation EnVision
Doublestain Kit (code K1395; Dako North America,
Carpinteria, CA, USA) according to the manufacturer’s
instructions. The synovial tissue was incubated with the
first primary antibody (anti-MIF; R&D Systems) and
polymer method, and the final color product was
developed using aminoethyl carbazole (Dako). The second
primary antibody (anti-p38; Santa Cruz Biotechnology)
was placed on the sections at room temperature for 1
hour, followed by a standard immunohistochemical
alkaline phosphatase method, and the color reaction
was developed with fast blue. No counterstain was used,
and the sections were mounted in an aqueous mounting
medium. Samples were photographed with an Olympus
photomicroscope.
Statistical analysis
The results were expressed as the mean ± SEM. Statistical
analysis was performed using Student’s ttest and Wilcoxon
signed-rank test. p< 0.05 was regarded as significant. 
RESULTS
ConA-induced MIF production in RA synovial
fibroblasts
To evaluate activated MIF production in RA synovial
fibroblasts, we incubated RA synovial fibroblasts with
various concentrations of ConA (0, 1, 5, or 10 µg/mL) for
24 hours, and the MIF concentration was measured in the
culture supernatant using sandwich ELISA. Stimulation of
synovial fibroblasts by ConA increased the production of
MIF in a dose-dependent manner (Fig. 1A). To measure
MIF mRNA expression, RA synovial fibroblasts were
stimulated with ConA for 12 hours, and the MIF mRNA
level was measured using semi-quantitative RT-PCR.
GAPDH mRNA was used as the internal control for even
loading. The pattern of mRNA expression was similar to
that of MIF production measured by ELISA (Fig. 1B).
Effect of cytokines on the production of MIF in RA
synovial fibroblasts
The effect of various inflammatory cytokines on MIF
production was determined. RA synovial fibroblasts were
incubated with IL-17 (10 ng/mL), IFN-γ (10 ng/mL),
CD40 ligand (CD40L, 10 ng/mL), IL-15 (10 ng/mL), IL-1β
(10 ng/mL), TNF-α (1 ng/mL), or transforming growth
factor-β (TGF-β, 10 ng/mL) for 48 hours, and the
concentration of MIF in the culture supernatant and the
MIF mRNA level were measured using ELISA and real-
time PCR, respectively. Inflammatory cytokines IL-17, IL-
15, TNF-α, IL-1β, and IFN-γ or costimulatory molecule
CD40L, which are involved in the pathogenesis of RA,
increased production of MIF (Fig. 1C) and expression of
MIF mRNA (Fig. 1D). Angiogenic cytokine TGF-β in RA
synovium also increased MIF production (p < 0.01) and
mRNA expression (p< 0.01).
Effects of signal inhibitors on the production of
MIF in RA synovial fibroblasts
To determine which signal transduction pathway
is involved in the induction of MIF, we used 10 nM
LY294002, which antagonizes the activation of the PI3
kinase-Akt pathway, 10 nM SB203580, which antagonizes
the activation of p38 MAP kinase, SP600125, which
antagonizes the activation of JNK, and 300 µM PDTC,
which antagonizes the activation of NF-κB. RA synovial
fibroblasts were preincubated for 1 hour with the
antagonist and then stimulated with 10 µg/mL of ConA
for 24 hours. The production of MIF was measured in
culture supernatants using the sandwich ELISA, and the
expression of MIF mRNA was measured using RT-PCR in
the synovial fibroblasts. MIF production decreased
significantly after antagonism of p38 MAP kinase (p <
0.005), PI3K/Akt, and NF-κB (p < 0.05, Fig. 2A). The
expression of MIF mRNA decreased significantly after
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Figure 1. Effects of concanavalin A (ConA) and cytokines on production of migration inhibitory factor (MIF) in rheumatoid arthritis
(RA) synovial fibroblasts. (A) RA synovial fibroblasts were treated with ConA (1 to 10 µg/mL) for 24 hours, and MIF concentration was
measured in culture supernatants by sandwich ELISA. (B) RA synovial fibroblasts were treated with ConA for 12 hours, and MIF
mRNA level was analyzed using RT-PCR. GAPDH mRNA was used as the internal control for even loading. Bars show the mean ± SEM
of five separate experiments. Production of MIF by the synovial fibroblasts increased in a dose-dependent manner. (C) RA synovial
fibroblasts were incubated with interferon (IFN)-γ, CD40L, interleukin (IL)-15, IL-1β, tumor necrosis factor (TNF)-α, or transforming
growth factor (TGF)-β, and the concentration of MIF in the culture supernatant was measured using sandwich ELISA. (D) Expression




Bantagonism of p38 MAP kinase (p < 0.05, Fig. 2B). These
results show that MIF production in RA synovial fibroblasts
is regulated mainly via p38 MAP kinase.
Activation of p38 MAP kinase requires phosphorylation,
therefore, we investigated the phosphorylation of p38
MAP kinase after ConA stimulation in RA synovial
fibroblasts. RA and OA synovial fibroblasts were cultured
with stimulation by 10 µg/mL of ConA for 1 hour. Cell
lysates were analyzed for p38 MAP kinase activation by
Western blotting of total and Tyr182-phosphorylated p38
MAP kinase (phospho-p38 MAP kinase) using specific
antibodies. The phospho-p38 MAP kinase level was
normalized to that of p38 MAP kinase and β-actin in the
same sample and compared at each time. ConA induced
phosphorylation of p38 MAP kinase in RA, but not in OA
synovial fibroblasts (data not shown). However, the
ConA-induced phosphorylation of p38 MAP kinase was
reduced after treatment with SB203580 (Fig. 3A). 
Expression of MIF and P38 in RA synovium and
synovial fibroblasts
We observed the constitutive expression of MIF in RA
synovial tissues using immunohistochemical staining. In
the synovial tissues, more intense staining of MIF and p38
MAP kinase was observed in the RA intima and subintima
compared with the OA synovium (Fig. 3B). Some cells that
were positively stained with MIF (red) also expressed p38
MAP kinase (fast blue), which revealed the existence of
merged cells (purple) that co-expressed MIF and P38 (Fig
3B).
DISCUSSION
Since MIF was first identified in 1966, its influence on
the pathogenesis of many diseases, including RA, has
been investigated extensively [20,21]. Many studies have
shown that MIF plays a pro-inflammatory role in many
inflammatory diseases, such as sepsis [22-24], RA [7,15,25,
26], delayed-type hypersensitivity [27], glomerulonephritis
[28-30], and various tumors [31-34]. In the pathogenesis
of RA, MIF regulates RA synovial hyperplasia directly and
by its effects on TNF-α and IL-1β, and activation of T cells
[8,35].
MIF is released from T cells, macrophages, fibroblast-
like synoviocytes, and endothelial cells in patients with RA
and has both paracrine and autocrine actions that stimulate
the activation of these cells [8]. It is also overexpressed in
serum, synovial fluid, cultured synovial fibroblasts, and
synovial tissues of RA patients [7,15,36]. One study has
shown that MIF immunostaining of RA synovium correlates
with the disease activity of RA, as assessed by C-reactive
protein (CRP) concentration, tenderness, and swollen joint
count [15]. In our previous study, the synovial concentration
of MIF was correlated with erythrocyte sedimentation
rate, CRP concentration, and oral steroid dosage, and synovial
MIF was upregulated in patients with radiographic bony
erosions [14]. These data suggest that MIF plays an
important role in RA pathogenesis and that its expression
reflects the clinical state of disease.
Although the membrane receptor for MIF has not been
extensively studied, the intracellular signal transduction
pathways for MIF are partially understood. One experi-
mental study has shown that MIF binds to the extracellular
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Figure 2. Effects of inhibition of intracellular signal molecules on the induction of migration inhibitory factor (MIF) in rheumatoid
arthritis (RA) synovial fibroblasts. RA synovial fibroblasts were treated with inhibitors of signal molecules for 1 hour and then stimulated
with concanavalin A (ConA; 10 µg/mL) for 24 hours. (A) Concentration of MIF was measured in culture supernatant using sandwich
ELISA. Bars show the mean ± SEM of three separate experiments. (B) Expression of MIF mRNA was determined using RT-PCR.
GAPDH mRNA was used as the internal control. MIF production and mRNA expression decreased significantly after inhibition of p38
mitogen-activated protein (MAP) kinase. In contrast, inhibition of phosphoinositide 3-kinase (PI3K)-Akt, nuclear factor-κB (NF-κB),
and c-Jun N-terminal kinase (JNK) activity had no effect on the expression of MIF mRNA.
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Figure 3. Phosphorylation of p38 mitogen-activated protein (MAP) kinase in rheumatoid arthritis (RA) synovial fibroblasts. (A) RA
synovial fibroblasts were cultured with or without concanavalin A (ConA) stimulation (10 µg/mL) for 1 hour. Lysates were examined
for p38 MAP kinase activation by Western blotting with p38 MAP kinase phosphospecific antibodies. Total p38 MAP-kinase-specific
antibody was used to verify equal protein loading. Lane 1, RA synovial fibroblasts without ConA treatment; lane 2, RA synovial
fibroblasts with ConA treatment; lane 3, treatment with ConA and p38 MAP kinase inhibitor SB203580 (10 nM). Data shown here
represent one of three independent experiments. (B) Expression of migration inhibitory factor (MIF) and p38 MAP kinase increased in
the RA synovium. Expression of MIF and p38 MAP kinase in the RA and osteoarthritis (OA) synovium was detected using
immunohistochemical staining. All tissues were counterstained with hematoxylin (× 400). (a) Staining for MIF in RA synovium, (b)
staining for p38 MAP kinase in RA synovium, (c) isotype control in RA synovium, (d) hematoxylin and eosin staining in RA synovium,
(e) staining for MIF in OA synovium, (f) staining for p38 MAP kinase in OA synovium, (g) isotype control in OA synovium, (h) H & E


























p38 lsotype control H & Edomain of CD74, a type II transmembrane protein with
high affinity, and that CD74 is required for MIF-induced
activation of intracellular signal transduction pathways
and cell activation and proliferation [37]. The transcriptional
co-activator, c-Jun activation domain-binding protein 1,
has been identified as an intracellular receptor protein for
MIF, and the ERK MAP kinase pathway as the MIF-
mediated signaling pathway [17].
TNF-α, IL-1, and IL-6 induce activation of ERK, JNK,
and p38 MAP kinase in cultured human synovial cells
[38]. In contrast, IFN-γ, IL-4, IL-10, and TGF-β do not
activate these signal pathway molecules [39]. P38 MAP
kinase is activated in response to IL-1β and TNF-α in
human synovial fibroblasts and is also involved in IL-6
and IL-8 synthesis [40,41]. The double phosphorylation
and translocation from the cytosol into the nucleus of
p38 MAP kinase result in the initiation of transcription
by binding to regulatory sites on DNA. Thus, activation of
pro-inflammatory cytokines such as TNF-α, IL-1, IL-6,
and IL-8 plays a central role in the pathogenesis of RA. In
addition, an inhibitor of the activation of p38 MAP kinase,
SB 203580, blocks the production and action of IL-6 and
IL-8 in synovial fibroblasts [41] and TNF-α and IL-1 in
bone and cartilage [42,43]. The potent inhibitor of p38
MAP kinase, FR167653, prevented onset of arthritis in
a prophylactic treatment model and suppressed the
progression of joint destruction in a therapeutic treatment
model [44].
As far as we are aware, no studies have examined the
signal transduction pathway involved in the production
of MIF. In the pathogenesis of RA, the p38 MAP kinase
pathway has an important role in the regulation of pro-
inflammatory cytokines, synthesis of MMPs, formation of
osteoclasts, and activation of endothelial cells. As a result,
p38 MAK kinase is involved in synovial inflammation,
cartilage degradation, inflammatory bone loss, and
angiogenesis [45]. In this study, we observed that MIF
production decreased significantly after inhibition of p38
MAP kinase and partially after inhibition of Akt and
NF-κB; however, inhibition of JNK had no effect on MIF
production in RA synovial fibroblasts. These results suggest
that the p38 MAP kinase pathway is a main pathway in
the induction of MIF in RA.
MAP kinase signaling has been found at distinct sites in
synovial tissue, and p38 MAP kinase activation has been
observed in the synovial lining and endothelial cells. We
also found that ConA induced phosphorylation of p38
MAP kinase in RA synovial fibroblasts, but not in OA
synovial fibroblasts. MIF actives RA FLSs to express
COX-2 and IL-6 via p38 MAP kinase, and MIF regulates
glucocorticoid sensitivity in macrophages, also via p38
MAP kinase [18,46]. Taken together, previous data and
our own suggest that inhibition of p38 MAP kinase is
effective in regulating induction of MIF expression and
MIF-induced gene activation. The expression of MIF and
p38 MAP kinase was upregulated in the RA synovium.
ConA stimulation induced MIF mainly through a p38
MAP-kinase-dependent pathway in RA synovial fibroblasts.
The inhibition of p38 MAP kinase might be effective in
regulating the induction of MIF expression and induced
gene activation.
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